Controlled Attenuation Parameter for Quantification of Steatosis: Which Cut-Offs to Use?

Area of Science:

• Hepatology
• Medical Imaging
• Diagnostic Technologies

Background:

• Chronic liver diseases (CLDs) represent a significant public health concern, often remaining undiagnosed.
• Hepatic steatosis (HS) is a key factor in fibrosis progression across various CLD etiologies, necessitating accurate detection and quantification.
• The Controlled Attenuation Parameter (CAP) is a noninvasive ultrasound-based method for assessing liver steatosis.

Purpose of the Study:

• To review published studies on the performance of CAP for quantifying hepatic steatosis.
• To identify and suggest reliable cut-off values for CAP measurements in clinical practice.
• To address the variability in existing CAP cut-off values due to diverse CLD etiologies and steatosis prevalence.

Main Methods:

• Systematic review of published research on CAP performance in quantifying hepatic steatosis.
• Analysis of studies reporting CAP accuracy across different chronic liver disease types.
• Evaluation of factors contributing to the heterogeneity of CAP cut-off values.

Main Results:

• CAP is a feasible, well-accepted, and cost-effective noninvasive technique for HS quantification.
• Significant variability exists in reported CAP cut-off values, limiting its routine clinical utility.
• The review aims to consolidate findings to propose more consistent and clinically applicable CAP thresholds.

Conclusions:

• Standardized CAP cut-off values are crucial for improving the clinical management of hepatic steatosis in CLDs.
• Further research is needed to validate proposed cut-off values across diverse patient populations and CLD etiologies.
• Optimizing CAP utility can enhance early detection and management of liver disease progression.